16.5 Psychotropic Pharmacology & Cardiac Safety
Key Takeaways
- Sertraline is the best-studied antidepressant in post-myocardial-infarction patients and, with escitalopram, is generally preferred for cardiac safety.
- Citalopram carries dose-dependent QT prolongation, with the FDA limiting the dose to 20 mg daily in adults over 60 and in hepatic impairment or CYP2C19 poor metabolizers.
- SSRIs impair platelet serotonin uptake and increase bleeding risk, which is clinically relevant in patients on dual antiplatelet therapy or anticoagulants.
- Tricyclic antidepressants cause orthostatic hypotension, anticholinergic effects, and QT prolongation with proarrhythmic potential, and are generally avoided after myocardial infarction.
- Antidepressants require 4 to 6 weeks for full effect and should never be stopped abruptly; paroxetine and venlafaxine in particular produce a marked discontinuation syndrome.
16.5 Psychotropic Pharmacology & Cardiac Safety
[!NOTE] Blueprint anchors: Domain 8 (Psychosocial Management), task 8.5 — Identify psychosocial medications and their common side effects; and task 8.10 — Reinforce the importance of psychosocial medication adherence.
Depression affects roughly one in five patients after myocardial infarction and independently predicts mortality, so many CR participants are taking psychotropic medication. These drugs interact with cardiac medications, alter heart rate and blood pressure responses to exercise, and affect bleeding risk and QT interval. The CR professional does not prescribe or adjust them — but is often the clinician who sees the patient most frequently and is best positioned to recognize a problem and reinforce adherence.
SSRIs: The First-Line Class
Selective serotonin reuptake inhibitors are first-line for depression in cardiac patients.
| Agent | Cardiac considerations |
|---|---|
| Sertraline | Best-studied in post-MI patients; favorable cardiac safety profile; commonly preferred |
| Escitalopram | Also generally preferred; well tolerated |
| Citalopram | Dose-dependent QT prolongation. FDA limits the dose to 20 mg/day in adults over 60, in hepatic impairment, and in CYP2C19 poor metabolizers or with concurrent CYP2C19 inhibitors |
| Fluoxetine | Long half-life; potent CYP2D6 inhibitor |
| Paroxetine | Potent CYP2D6 inhibitor; most anticholinergic of the SSRIs; marked discontinuation syndrome |
Class effects to recognize
- Bleeding risk: SSRIs block platelet serotonin uptake, impairing platelet aggregation. Combined with aspirin plus a P2Y12 inhibitor or with an anticoagulant, this meaningfully raises bleeding risk. Watch for bruising, gingival bleeding, epistaxis, and GI bleeding, and report them.
- Hyponatremia (SIADH), particularly in older adults and with concurrent diuretics — presents as confusion, weakness, falls, or seizures.
- GI upset, sexual dysfunction, initial anxiety or activation, sleep disturbance.
- Serotonin syndrome with serotonergic combinations — agitation, hyperreflexia, clonus, hyperthermia, autonomic instability.
[!WARNING] CYP2D6 interaction with metoprolol. Fluoxetine and paroxetine potently inhibit CYP2D6, the enzyme that metabolizes metoprolol. Co-prescription raises metoprolol levels and can produce bradycardia, fatigue, hypotension, and a further blunted heart rate response to exercise. A CR patient who becomes unusually bradycardic or exercise-intolerant after starting one of these SSRIs should have the interaction flagged to the prescriber. Carvedilol is also a CYP2D6 substrate.
Other Antidepressant Classes
| Class / agent | Key cardiac-relevant effects |
|---|---|
| SNRIs (venlafaxine, duloxetine) | Dose-dependent blood pressure elevation — monitor BP, particularly at higher venlafaxine doses; also useful for neuropathic pain (duloxetine) |
| Tricyclics (amitriptyline, nortriptyline) | Orthostatic hypotension, anticholinergic effects (dry mouth, urinary retention, constipation, confusion), QT prolongation and proarrhythmia; generally avoided post-MI; amitriptyline is frequently prescribed at low dose for neuropathic pain or insomnia, so ask specifically |
| Bupropion | No sexual dysfunction, weight-neutral or reducing; also first-line for smoking cessation; lowers seizure threshold (contraindicated with seizure disorder, bulimia, anorexia); can raise blood pressure |
| Mirtazapine | Sedation and appetite stimulation with weight gain — sometimes deliberately chosen for the underweight, poorly sleeping patient; orthostatic hypotension |
| Trazodone | Widely used at low dose for insomnia; orthostatic hypotension, sedation, rare priapism |
Anxiolytics, Antipsychotics, and Mood Stabilizers
Benzodiazepines
Effective acutely but problematic chronically: sedation, impaired balance and falls, cognitive impairment, tolerance, and dependence, with a difficult and potentially dangerous withdrawal. They appear on the Beers criteria as potentially inappropriate in older adults. In a CR gym, a benzodiazepine-sedated patient is a fall risk on a treadmill. Never advise abrupt discontinuation — refer to the prescriber for a taper.
Antipsychotics
QT prolongation (notably with ziprasidone, haloperidol, and others) and metabolic effects — weight gain, dyslipidemia, insulin resistance, and new-onset diabetes, especially with olanzapine and clozapine. These directly worsen the cardiovascular risk profile CR is trying to improve, so weight, lipids, and glucose deserve closer monitoring in patients taking them.
Lithium
Narrow therapeutic index. Levels rise with dehydration, sodium depletion, thiazide diuretics, NSAIDs, and ACE inhibitors or ARBs — a combination that is common in cardiac patients and directly relevant to exercise-related fluid loss. Toxicity presents as tremor, ataxia, confusion, vomiting, and arrhythmia. Counsel on consistent hydration and sodium intake, and flag heat exposure and heavy sweating to the prescriber.
Adherence: The CR Professional's Main Lever
Adherence to antidepressants is poor, and the reasons are predictable and addressable:
| Barrier | Counseling response |
|---|---|
| "It isn't working" at 1-2 weeks | Antidepressants require 4 to 6 weeks for full effect; some improvement in sleep and appetite precedes mood change |
| "I feel better, so I stopped" | Feeling better means the medication is working; continuation for months after remission is standard to prevent relapse |
| Side effects early | Nausea, headache, and activation often attenuate over 1 to 2 weeks; report persistent effects to the prescriber rather than stopping |
| Stigma | Normalize: depression after a cardiac event is common and independently affects survival; treating it is cardiac care |
| Cost | Screen for cost-related non-adherence; most SSRIs are inexpensive generics |
| Polypharmacy burden | Simplify timing where possible; use pill organizers |
[!WARNING] Never advise a patient to stop a psychotropic abruptly. SSRI and SNRI discontinuation syndrome — dizziness, "brain zaps," flu-like symptoms, irritability, insomnia — is particularly pronounced with paroxetine and venlafaxine due to short half-lives. Abrupt benzodiazepine withdrawal can cause seizures. Any change belongs to the prescriber.
Scope boundary
[!IMPORTANT] The CR professional's role is to recognize, monitor, report, and reinforce — not to prescribe, adjust, or discontinue. Monitor orthostatic vital signs, heart rate response during exercise, bleeding signs, sedation and fall risk, and weight and glucose trends; report changes to the prescriber; and reinforce adherence with accurate information about onset and duration of therapy.
Realistic Clinical Scenario
Scenario: A 59-year-old woman 6 weeks post-MI is on aspirin, ticagrelor, metoprolol, atorvastatin, and lisinopril. Her PHQ-9 was 16 at intake, and her primary care physician started paroxetine 20 mg two weeks ago. She now reports fatigue, and her resting heart rate has fallen from 68 to 52 bpm with a markedly blunted rate response during exercise. She has new gum bleeding when brushing. She tells you she is going to stop the paroxetine because "it's making me tired and it isn't helping anyway."
Analysis: Three distinct issues converge. First, paroxetine is a potent CYP2D6 inhibitor and metoprolol is a CYP2D6 substrate — the new bradycardia, fatigue, and blunted exercise heart rate response are highly consistent with elevated metoprolol levels from this interaction. Second, the gum bleeding reflects the additive bleeding risk of an SSRI on top of dual antiplatelet therapy with aspirin and ticagrelor. Third, at two weeks she is inside the normal 4-to-6-week window before full antidepressant effect, so "it isn't helping" is an expectation problem, not a treatment failure — and paroxetine has one of the most pronounced discontinuation syndromes, so stopping abruptly would be actively harmful.
Plan: Advise her explicitly not to stop the medication on her own and explain why — both that the benefit takes 4 to 6 weeks and that abrupt paroxetine cessation causes withdrawal symptoms. Contact the prescriber the same day to report the suspected CYP2D6 interaction with metoprolol, the bradycardia and blunted exercise response with specific heart rate values, and the new bleeding, noting that an alternative SSRI such as sertraline or escitalopram avoids the CYP2D6 issue — but leave the decision to the prescriber. Meanwhile, prescribe exercise intensity by RPE and the talk test rather than heart rate given her unreliable chronotropic response, monitor orthostatic vital signs, and document the bleeding. Re-administer the PHQ-9 at the 30-day update to track response objectively.
A patient on metoprolol develops new bradycardia at 52 bpm, fatigue, and a markedly blunted exercise heart rate response two weeks after starting paroxetine. What is the most likely explanation?
A patient two weeks into sertraline therapy says she plans to stop it because it "isn't working." What is the most appropriate counseling response?
Which combination represents a clinically important safety concern in a post-MI patient taking aspirin and ticagrelor?